Work Programs Commence to Unlock Tantalum as a High-Value By-Product Critical Metal Opportunity
Shaakichiuwaanaan rapidly evolving into an emerging critical minerals powerhouse, with workstreams now underway on caesium, tantalum, and gallium opportunities MONTREAL, June 25, 2025 /PRNewswire/ -- June 26, 2025 – Sydney, Australia Highlights...
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings...
UBTS and Cuber AI Launch Exploratory Study into Next-Gen Agentic AI for Logistics Innovation
Joint initiative to evaluate Agentic AI-driven transformation of supply chain operations across ASEAN SINGAPORE, May 30, 2025 /PRNewswire/ -- UBTS Pte Ltd, a leading Singapore homegrown logistics player, has embarked on an exploratory partnership...
NYSE Content Advisory: Pre-Market update + Hinge Health, MNTN pop double digits in trading debuts
NEW YORK, May 23, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer...
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. These...
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative,...
Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with...
Global Times: Exclusive interview with renowned Chinese sculptor and NAMOC Director Wu Weishan
BEIJING, May 19, 2025 /PRNewswire/ -- In recent years, Chinese culture has been blooming in all its diversity, continuously achieving remarkable success overseas. In this Cultural Outreach Talk series, the Global Times invites insiders from...
Danish Government awards Norne Thorning Storage the License to explore the possibility of CO2 storage in Jutland
COPENHAGEN, Denmark, April 11, 2025 /PRNewswire/ -- Norne Thorning Storage ApS ("Norne"), a Fidelis New Energy, LLC company, has been awarded the Exploration License for the Thorning structure by the Danish Minister of Climate, Energy and Utilities....
Dataloy Systems Partners with Lloyd's List Intelligence to Embed Risk Intelligence into Voyage Management
BERGEN, Norway, April 8, 2025 /PRNewswire/ -- Dataloy Systems, a trusted leader in innovative voyage management solutions, today announced a strategic partnership with Lloyd's List Intelligence, a global authority in maritime risk and compliance...